What’s Happening
Pharmaceutical company Amgen said its experimental drug for Sjögren’s disease succeeded in a late-stage clinical trial.
The drug, called dazodalibep, met the main goal of the study. Patients who received the treatment showed a significant improvement in their disease activity compared with those who received a placebo.
The results are an important step for Amgen because Sjögren’s disease is a condition with limited treatment options in the United States.
Amgen’s shares rose about 4% after the results were announced.
What Is Sjögren’s Disease?
Sjögren’s disease is an autoimmune condition.
Normally, the immune system protects the body from infections and other threats. With an autoimmune disease, the immune system mistakenly attacks the body's own cells and tissues.
In Sjögren’s disease, the immune system mainly attacks the glands that produce moisture.
This can cause:
- Dry eyes
- Dry mouth
- Fatigue
- Joint and muscle pain
- Dryness in other parts of the body
The disease affects about 1% of the global population and mostly affects women.
Despite affecting millions of people, there are currently no approved treatments in the United States specifically designed to treat the underlying cause of Sjögren’s disease.
How Did Amgen’s Drug Perform?
In the late-stage trial, patients received dazodalibep for 48 weeks.
Amgen said the treatment produced a statistically significant and clinically meaningful improvement in disease activity.
In simple terms, the results were strong enough statistically that the improvement was unlikely to be explained simply by chance.
The company also said that most of the side effects reported during the study were mild to moderate.
Only a relatively small number of patients stopped taking the drug because of side effects.
However, the results from this trial alone do not mean the drug is ready for patients.
Amgen still needs to complete additional testing and work with regulators before the drug could potentially be approved.
Why Is This Trial Important?
Sjögren’s disease has been a difficult area for drug development.
One problem researchers face is what is known as a high placebo response.
A placebo is a treatment that does not contain the active drug being tested. In clinical trials, some patients who receive a placebo can still report improvements in their symptoms.
When many patients in the placebo group improve, it becomes harder for researchers to show that an experimental drug is responsible for the improvement.
Because of this challenge, positive results from a late-stage trial can be particularly important for companies developing treatments for the disease.
Amgen Has Another Trial Underway
Amgen is not finished testing dazodalibep.
The company is also conducting another late-stage study called OASIZ 303.
This trial is testing the drug in patients with Sjögren’s disease who have a moderate-to-severe burden of symptoms.
Results from the study are expected in the fourth quarter of 2026.
The second trial will be important because analysts expect Amgen may need positive results from two late-stage studies before it can seek approval from the U.S. Food and Drug Administration.
Amgen is expected to provide more information about its regulatory plans after the results from OASIZ 303 become available.
Competition Is Growing
Amgen is not the only pharmaceutical company developing a treatment for Sjögren’s disease.
Novartis and Johnson & Johnson are also developing potential treatments for the condition.
This means that Amgen could face competition if its drug eventually receives approval.
Researchers and investors will likely compare the results of these different treatments to understand how well each drug works and how safe they are.
Novartis is developing an experimental drug called ianalumab, which is also being studied for Sjögren’s disease.
Amgen plans to present more detailed results from its study at an upcoming medical meeting.
What’s Changing / Business Impact
The successful trial gives Amgen another potential opportunity in the autoimmune disease market.
If future trials are also successful, dazodalibep could potentially become a new treatment option for people with Sjögren’s disease.
For Amgen, this could expand its presence in the autoimmune treatment market and create a new commercial opportunity.
For the wider healthcare industry, successful development of a treatment could also increase activity around Sjögren’s disease.
Pharmaceutical companies, healthcare providers, insurers and other healthcare organizations may pay greater attention to the disease as new treatments move closer to the market.
However, the drug still has to pass additional testing and regulatory review before it can become an approved treatment.
Why This Matters
The results are important because Sjögren’s disease affects a large number of people but has limited treatment options.
A medicine that successfully targets the underlying disease could provide a new option for patients rather than only managing individual symptoms such as dryness and pain.
The results are also important for Amgen because the company is continuing to build its pipeline of potential treatments.
But one successful clinical trial does not guarantee approval.
The FDA will eventually need to review the full body of evidence, including results from other clinical studies, to determine whether the benefits of the treatment outweigh its risks.
Looking Ahead
Amgen's next major milestone will be the results of the OASIZ 303 trial, which are expected in the fourth quarter of 2026.
The company is also expected to present more detailed data from the successful trial at an upcoming medical meeting.
These results will provide more information about the drug's effectiveness and safety and could help Amgen determine its next steps toward potential FDA approval.
The company will also need to consider the competitive environment, as other pharmaceutical companies are developing treatments for the same disease.
What This Means for Healthcare Marketers
For healthcare marketers, Amgen's clinical trial results demonstrate how drug development milestones can create changes across a healthcare market.
When an experimental drug moves closer to potential approval, the company may begin preparing for a new stage of business activity.
Healthcare marketers should watch signals such as:
- Clinical trial results
- Regulatory filings
- FDA decisions
- New competitors
- Pharmaceutical partnerships
- Potential drug launches
- Expansion into new treatment areas
These signals can help marketers understand when a healthcare company may be entering a period of growth or change.
For companies selling products or services to pharmaceutical and healthcare organizations, a major clinical milestone can also create new needs around commercialization, market access, sales, marketing, data and patient outreach.
The key is to look beyond the headline and understand what the development means for the company's next stage and what new business needs could emerge from it.
Key Takeaways
- Amgen's experimental drug dazodalibep succeeded in a late-stage trial for Sjögren’s disease.
- The drug met the study's main goal and showed a statistically significant and clinically meaningful improvement in disease activity.
- Sjögren’s disease is an autoimmune condition that can cause dry eyes, dry mouth, fatigue and pain.
- The disease affects about 1% of the global population and primarily affects women.
- The U.S. currently has no approved treatment specifically targeting the underlying cause of Sjögren’s disease.
- Amgen is conducting another late-stage trial, OASIZ 303, with results expected in Q4 2026.
- Novartis and Johnson & Johnson are also developing treatments for the disease.
- For healthcare marketers, clinical milestones can signal changes in a company's commercial plans, competitive environment and future business needs.